Serum Neopterin Levels and the Clinical Presentation of COVID-19

• DOI: 10.1515/pteridines-2020-0021
• Publication Date: 2022-11-14T12:06:41Z
• Authors: Deniz Öğütmen Koç; Hande Sipahi; Cemile Dilşah Sür...; Mustafa Çalık; Nilgün Bireroğlu; Sıla Öksüz; Terken Baydar; Gönül Şahin
• Keywords: Neopterin

Abstract In Coronavirus disease 2019 (COVID-19), it is important to evaluate activity and investigate possible biomarkers. Therefore, in this study, we investigated the relationship between serum levels of immune activation marker neopterin patients with COVID-19. The study enrolled 45 (23 females, 51.1%) treated for were divided into two groups according their clinical presentation: those who recovered quickly (Group 1) worsened progressively 2). C-reactive protein high all on admission. Group 1, concentrations neopterin/creatinine ratios significantly higher admission compared Day 14 disease, whereas 2, at than Neopterin 1. markedly a derived neutrophil–lymphocyte ratio (dNLR) > 2.8 dNLR ≤ ( p < 0.05). Serum can be used as prognostic biomarker predicting